Skinbright Active
£7.19 GBP (Inc VAT) /
Skinbright Active
£5.99 GBP (Ex VAT)
£7.19 GBP (Inc VAT)
/
£7.19 GBP (Inc VAT) /
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Minimum Shelf life:
About this product
PRODUCT DESCRIPTION
- Induces a significant lightening effect on the skin, at the same time that fights against photoaging.
- Acts by inhibiting tyrosinase activity.
- Exhibits a considerable lightening in-vivo effect on the skin.
- Has a completely safe profile.
- Shows good stability in formulations.
- Possesses a photoprotective effect on the human epidermal keratinocytes, helping to prevent skin damage caused by UV radiation.
- Unlike other skin brighteners/lighteners that can cause irritation and sensitivity due to the sun, Skinbright Active actually helps to prevent skin damage caused by UV radiation – 190% increase in cell viability.
- Exhibits a better depigmenting effect than Kojic Acid and Arbutin, and similar to Hydroquinone.
- Does not affect melanocyte growth, while Hydroquinone cytotoxicity was clearly observed.
- A cream containing 5% Skinbright Active induces a significant brightening effect after 30 and 60 days.
- Skinbright active reduced the appearance of melasma (dark skin discolourations that appears on sun-exposed areas of the face) by 72% and lentigines (sun spots, age spots or liver spots) by 67% after 60 days of treatment.
- Kojic Acid was very efficient but was found that it could cause skin damage so was recently banned in many countries. Skinbright Active has shown better efficiency than Kojic Acid and is very safe to use.
HOW TO USE IT
Heat stable.
Water or oil-soluble?
Oil-soluble.
Can I add it to oil serums or ready-made products?
Yes, mix it in thoroughly.
Storage and Shelf life
See label for best before date. Store cool and dark away from direct sunlight.
More information about Skinbright Active
The colour of our skin is determined mainly by the amount, distribution and type of melanin, a pigment produced by melanocyte cells in a process called melanogenesis. Melanin synthesis takes place in melanosomes, which contain specific enzymes controlling the production of pigments. The first step of melanogenesis is mediated by tyrosinase, a key enzyme that catalyses the first two reactions of melanin synthesis. Abnormal accumulation of melanin is responsible for hyperpigmentations, which can be distressing for some people.
Changes in skin pigmentation
Typical pigmentary changes apppear during intrinsic aging and photoaging. These may be a result of the abnormal accumulation of melanin or acute or persistent UV exposure.
In vivo tests - Brightening effect
20 healthy female volunteers aged 18 to 46, with a range of skin types were selected for this study. The volunteers applied a cream containing 0.1% Skinbright Active on one side of the face, twice daily, for 2 months, and a placebo cream on the other side.
The brightening effect was instrumentally evaluated by means of a Chromameter CR-300. Mean values from 5 successive measurements were calculated. These 6 measurements were rigorously made at the same location at each time.
Measurements were taken before application, after 30 days and after 60 days of treatment.
After 30 days of treatment, there was significant increase in skin luminance for the skin that was treated with Skinbright Active Cream. The placebo cream presented no significant effects.
After 60 days of treatment, the brightening effect induced by the cream containing Skinbright Active increased in respect to the results at 30 days and it was significantly superior to the effect observed for the placebo cream. In short, the results of the in vivo test prove that Skinbright Active is able to induce a skin brightening effect after 30 and 60 days of treatment.
At the end of the study, no adverse effects were reported by the volunteers.
Skinbright Active showed no cytotoxic effects on melanocytes, keratinocytes or fibroblasts, neither mutagenicity nor any irritation or sensitisation reaction. Its efficacy was tested in cell-free enzymatic assays as well as in cell-based assays. It proved to inhibit both mushroom and endogenous human tyrosinase in vitro, and exhibited a significant depigmenting effect on human melanocytes. The product also proved to have a significant photo-protective effect on human epidermal keratinocyte cell cultures, and can therefore prevent the skin-damaging effects of ultraviolet radiation.
In conclusion, Skinbright Active can be classified as a safe skin brightening agent due to its impeccable safety profile and contrasted in vitro and in vivo efficacy.
TECHNICAL DOCUMENTS
Here is a link to all non batch specific documents for this product Link to Technical Documents
If you have any questions about the documents or need the Certificate of Analysis (COA) for a product which you have recived, then please request that here.